Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Research Advisory Committee on Gulf War Veterans' Illnesses


Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Research Update - July 2006


The following journal articles were distributed for review in July 2006.  You can access the article's abstract by copying the paper title and pasting it into the search bar of the PubMed website, linked here. 

Research Relevant to Gulf War Service and Exposures
1. Long-lasting T cell responses to biological warfare vaccines in human vaccines.   (Allen JS, et al.  Clin Infect Dis.  Jul 1, 2006; 43(1): 1-7.)
2. Predictors of incident chronic widespread pain among veterans following the first Gulf War.   (Ang DC , et al.  Clin J Pain.  Jul/Aug 2006; 22(6): 554-563)
3. Interpreting symptoms in military personnel after combat.   (Axelrod BN.  Lancet.  May 27, 2006; 367(9524): 1709-1710)
4. Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target.   (Barber SC , et al.  Biochim Biophys Acta.  Apr 4, 2006; [Epub ahead of print])
5. Why people believe they were exposed to biological or chemical warfare: a survey of Gulf War veterans.   (Brewer NT, et al.  Risk Anal.  Apr 2006; 26(2): 337-345)
6. Coding region paraoxonase polymorphisms dictate accentuated neuronal reactions in chronic, sub-threshold pesticide exposure.   (Browne RO, et al.  FASEB J.  Jun 28, 2006: [Epub ahead of print])
7. Sleep quality and the role of sleep medications for veterans with chronic pain.   (Chapman JB, et al.  Pain Med.  Mar-Apr 2006; 7(2): 105-114)
8. Defence ministry denies ignoring Gulf War syndrome in pension award.   (Dyer O.  BMJ.  Jun 24, 2006; 332(7556): 1472)
9. Interaction of pyridostigmine bromide and N,N-diethyl-m-toluamide alone and in combination with P-glycoprotein expressed in Escherichia coli leaky mutant.  (El-Masry EM, Abou-Donia MB .  J Toxicol Environ Health A.  May 2006; 69(10): 919-933)
10. Passive sampler-derived air concentrations for polybrominated diphenyl ethers and polycyclic aromatic hydrocarbons in Kuwait.   (Gevao B, et al.  Environ Toxicol Chem .  Jun 2006; 25(6): 1496-1502)
11. Concentrations and characteristics of depleted uranium in biological and water samples collected in Bosnia and Herzegovina.   (Jia G, et al.  J Environ Radioact .  Jun 23, 2006; [Epub ahead of print])
12. Medically evaluated psychological and physical health of Australian Gulf War veterans with chronic fatigue.   (Kelsall H, et al.  J Psychosom Res .  Jun 2006; 60(6): 575-584)
13. Acetylcholinesterase inhibition: does it explain the toxicity of organophosphorus compounds?   (Maxwell DM, et al.  Arch Toxicol .  Jun 13, 2006; [Epub ahead of print]}
14. Patterns of health care seeking of Gulf War registry members prior to deployment.   (Miller RN, et al.  Mil Med .  May 2006; 171(5): 370-375)
15. Pesticides induced oxidative stress in thymocytes.   (Olgun S, Misra HP.  Mol Cell Biochem .  May 23, 2006; [Epub ahead of print])
16. Demographics of and diagnoses in Operation Enduring Freedom and Operation Iraqi Freedom personnel who were psychiatrically evacuated from the theater of operations.   (Rundell JR.  Gen Hosp Psychiatry .  July-Aug 2006; 28(4): 352-356)
17. Paraoxonase cluster polymorphisms are associated with sporadic ALS.   (Saeed M, et al.  Neurology .  Jul 5, 2006; [Epub ahead of print])
18. Paraoxonase gene polymorphisms and sporadic ALS. (Slowik A, et al.  Neurology .  Jul 5, 2006; [Epub ahead of print])
19. Enhancement of an analytical method for the determination of squalene in anthrax vaccine adsorbed formulations.   (Spanggord RJ, et al.  J Pharm Biomed Anal .  Jun 6, 2006; [Epub ahead of print])
20. Multiple vaccine and pyridostigmine interactions: Effects on cognition, muscle function and health outcomes in marmosets.   (Stevens D, et al.  Pharmacol Biochem Behav.   Jun 23, 2006; [Epub ahead of print])
21. In vitro immune toxicity of depleted uranium: effects on murine macrophages, CD4+ T cells, and gene expression profiles.   (Wan B, et al.  Environ Health Perspect .  Jan 2006; 114(1): 85-91)
22. Neuroendocrine aspects of PTSD.   (Yehuda R.  Handb Exp Pharmacol .  2005; (169): 371-403)
23. Our recent experiences with sarin poisoning case in Japan and pesticide users with references to some selected chemicals.   (Yokoyama K.  Neurotoxicology .  May 2, 2006; [Epub ahead of print])

Research on Evaluation/Treatment of Chronic Multisymptom Illnesses
1. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia.   (Altindag O, Celik H.  Redox Rep.  2006; 11(3): 131-135)
2. A first study of cytokine genomic polymorphisms in CFS: positive association of TNF-857 and IFNgamma 874 rare alleles.   (Carlo-Stella N, et al.  Clin Exp Rheumatol.  Mar-Apr 2006; 24(2): 179-182)
3. Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial.   (Martin DP, et al.  Mayo Clin Proc.  Jun 2006; 81(6): 749-757)
4. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.   (McDermott C, et al.  QJM.  Jun 29, 2006; [Epub ahead of print])
5. To “lump” or to “split” the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?   (Moss-Morris R, Spence M.  Psychosom Med.  May-Jun 2006; 68(3): 463-469)
6. Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome.   (Rajeevan MS, et al.  Genes Brain Behav.  Jun 1, 2006; [Epub ahead of print])
7. Exposure to a specific pulsed low-frequency magnetic field: a double-blind placebo-controlled study of effects on pain ratings in rheumatoid arthritis and fibromyalgia patients.   (Shupak NM , et al.  Pain Res Manag.  Summer 2006; 11(2): 85-90)
8. Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup?   (Siegel SD , et al.   J Psychosom Res.  Jun 2006; 60(6): 559-566)
9. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on international classification of disease, 9th revision codes.   (Weir PT, et al.  J Clin Rheumatol.  Jun 2006; 12(3): 124-128)
10. Neuroimaging of functional somatic syndromes.   (Wood PB.  Int Rev Neurobiol.  2005; 67: 119-163)

Back to Previous Research Updates